GnRHR inhibits the malignant progression of triple-negative breast cancer by upregulating FOS and IFI44L

IF 3.4 2区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Genomics Pub Date : 2025-03-01 DOI:10.1016/j.ygeno.2025.111021

Caiping Chen , Li Xue , Chao Han , Wanxin Wu , Ning Lu , Xiang Lu

{"title":"GnRHR inhibits the malignant progression of triple-negative breast cancer by upregulating FOS and IFI44L","authors":"Caiping Chen , Li Xue , Chao Han , Wanxin Wu , Ning Lu , Xiang Lu","doi":"10.1016/j.ygeno.2025.111021","DOIUrl":null,"url":null,"abstract":"<div><div>Gonadotropin-releasing hormone receptor (GnRHR) has been identified as a factor that hinders the malignant advancement of triple-negative breast cancer (TNBC). Nevertheless, the specific molecular mechanism responsible for this impact remains unclear. This study demonstrates that GnRHR exhibits low expression levels in TNBC, which correlates with an unfavorable prognosis for patients. GnRHR promotes the expression of FOS, subsequently enhancing IFI44L transcription and expression, thereby inhibiting TNBC cell proliferation, migration, and invasion. Goserelin reduced the growth rate of TNBC tumors in nude mice, resulting in elevated levels of GnRHR, FOS, and IFI44L in tumor tissues, while the expression of Ki67, vimentin, and N-cadherin decreased. Overall, our results reveal that GnRHR suppresses the malignant progression of TNBC by upregulating FOS and IFI44L. Goserelin slows down the proliferation of TNBC tumors in vivo through the GnRHR/FOS/IFI44L pathway, which may present a new therapeutic approach for the management of TNBC.</div></div>","PeriodicalId":12521,"journal":{"name":"Genomics","volume":"117 2","pages":"Article 111021"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genomics","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0888754325000370","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Gonadotropin-releasing hormone receptor (GnRHR) has been identified as a factor that hinders the malignant advancement of triple-negative breast cancer (TNBC). Nevertheless, the specific molecular mechanism responsible for this impact remains unclear. This study demonstrates that GnRHR exhibits low expression levels in TNBC, which correlates with an unfavorable prognosis for patients. GnRHR promotes the expression of FOS, subsequently enhancing IFI44L transcription and expression, thereby inhibiting TNBC cell proliferation, migration, and invasion. Goserelin reduced the growth rate of TNBC tumors in nude mice, resulting in elevated levels of GnRHR, FOS, and IFI44L in tumor tissues, while the expression of Ki67, vimentin, and N-cadherin decreased. Overall, our results reveal that GnRHR suppresses the malignant progression of TNBC by upregulating FOS and IFI44L. Goserelin slows down the proliferation of TNBC tumors in vivo through the GnRHR/FOS/IFI44L pathway, which may present a new therapeutic approach for the management of TNBC.

查看原文本刊更多论文

GnRHR通过上调FOS和IFI44L抑制三阴性乳腺癌的恶性进展。

促性腺激素释放激素受体（GnRHR）已被确定为阻碍三阴性乳腺癌（TNBC）恶性进展的一个因素。然而，造成这种影响的具体分子机制仍不清楚。本研究表明，GnRHR在TNBC中表达水平较低，这与患者预后不良有关。GnRHR促进FOS的表达，进而增强IFI44L的转录和表达，从而抑制TNBC细胞的增殖、迁移和侵袭。Goserelin降低裸鼠TNBC肿瘤的生长速度，导致肿瘤组织中GnRHR、FOS、IFI44L水平升高，而Ki67、vimentin、N-cadherin表达降低。总之，我们的研究结果表明，GnRHR通过上调FOS和IFI44L来抑制TNBC的恶性进展。Goserelin通过GnRHR/FOS/IFI44L通路在体内减缓TNBC肿瘤的增殖，这可能为TNBC的治疗提供新的治疗途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genomics 生物-生物工程与应用微生物

CiteScore

9.60

自引率

2.30%

发文量

260

审稿时长

60 days

期刊介绍： Genomics is a forum for describing the development of genome-scale technologies and their application to all areas of biological investigation. As a journal that has evolved with the field that carries its name, Genomics focuses on the development and application of cutting-edge methods, addressing fundamental questions with potential interest to a wide audience. Our aim is to publish the highest quality research and to provide authors with rapid, fair and accurate review and publication of manuscripts falling within our scope.